Official_Bellicum_Logo_RGB.jpg
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 janv. 2023 18h43 HE | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 janv. 2023 16h36 HE | Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
22157.jpg
Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: FDA and EMA Special Drug Designations to Ignite R&D Progress
27 janv. 2023 04h58 HE | Research and Markets
Dublin, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
26 janv. 2023 14h05 HE | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Ryan Davies Conducts CEO Chat with Leading Biotech IP Expert
20 janv. 2023 03h01 HE | CancerVAX, Inc
LEHI, Utah, Jan. 20, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., a pre-clinical biotechnology company developing immunotherapy cancer treatments that use the body’s immune system to fight cancer,...
EVAXION_BLACK_RGB.jpg
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
19 janv. 2023 08h45 HE | Evaxion Biotech
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Cancer Gene Therapy Market
Cancer Gene Therapy Global Market Report 2022: Featuring Amgen, Novartis, Gilead Sciences, GlaxoSmithKline & More
19 janv. 2023 06h33 HE | Research and Markets
Dublin, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.The cancer gene therapy market is...
Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer
17 janv. 2023 04h00 HE | AKAMPION
- Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 - Pan Cancer T B.V., a...
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
17 janv. 2023 04h00 HE | AKAMPION
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...
PDS Biotech Logo.png
PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference
13 janv. 2023 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...